Baidu
map

JACC:心衰患者左室射血分数的远期变化动态曲线

2018-07-31 MedSci MedSci原创

心衰病人远期的左室射血分数(LVEF)变化曲线尚不清楚。本研究的目的旨在评估心衰伴左室射血分数降低(<40%)和中等范围LVEF(40%-49%)患者的LVEF随访15年的变化曲线。本研究纳入了1160例心衰门诊患者,在研究起始对所有患者进行了超声心动图检查,1年后建立时间计划表,之后每2年随访一次直至15年。最终,每个患者的平均LVEF测量次数为3.6 ± 1.7次,整体来看,患者LVEF的变化

心衰病人远期的左室射血分数(LVEF)变化曲线尚不清楚。本研究的目的旨在评估心衰伴左室射血分数降低(<40%)和中等范围LVEF(40%-49%)患者的LVEF随访15年的变化曲线。

本研究纳入了1160例心衰门诊患者,在研究起始对所有患者进行了超声心动图检查,1年后建立时间计划表,之后每2年随访一次直至15年。最终,每个患者的平均LVEF测量次数为3.6 ± 1.7次,整体来看,患者LVEF的变化曲线呈倒U型,第一年的LVEF上升幅度最大,直至10年,之后的LVEF呈轻度下降趋势(p <0.001)。该曲线在非缺血心衰患者和女性患者中更典型。新发的心衰患者(≤12个月)在早期的LVEF上升幅度更大,而缺血性心衰患者第一年内LVEF的上升幅度更小。与心衰伴左室射血分数降低患者相比,心衰伴中等范围LVEF患者的第一年LVEF上升幅度更小(p <0.001),但两组患者的曲线在15年后基本一致。

本研究结果显示,心衰患者的左室射血分数变化曲线受不同疾病因素影响,但基本呈倒U型,两端的LVEF更低。

原始出处:

本文系梅斯医学(MedSci)原创编译整理,转载需授权

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1700464, encodeId=3ab61e004647d, content=<a href='/topic/show?id=49fa4801038' target=_blank style='color:#2F92EE;'>#左室射血分数#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48010, encryptionId=49fa4801038, topicName=左室射血分数)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccd530104305, createdName=liuxiaona, createdTime=Sat Oct 06 09:13:00 CST 2018, time=2018-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854111, encodeId=b05c185411118, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Fri May 10 07:13:00 CST 2019, time=2019-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325917, encodeId=5e25132591e49, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Thu Aug 02 06:13:00 CST 2018, time=2018-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373421, encodeId=865713e3421c2, content=<a href='/topic/show?id=2fd051939ab' target=_blank style='color:#2F92EE;'>#心衰患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51939, encryptionId=2fd051939ab, topicName=心衰患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Thu Aug 02 06:13:00 CST 2018, time=2018-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=335458, encodeId=9b203354581e, content=好文章学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b5a62240667, createdName=张新亮1853311252142e2fm, createdTime=Wed Aug 01 07:05:24 CST 2018, time=2018-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=335406, encodeId=4d65335406a5, content=学习啦, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ac82155377, createdName=1201e5c5m39暂无昵称, createdTime=Tue Jul 31 23:38:12 CST 2018, time=2018-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=335360, encodeId=0fa933536088, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba101609906, createdName=happsf, createdTime=Tue Jul 31 16:14:10 CST 2018, time=2018-07-31, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1700464, encodeId=3ab61e004647d, content=<a href='/topic/show?id=49fa4801038' target=_blank style='color:#2F92EE;'>#左室射血分数#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48010, encryptionId=49fa4801038, topicName=左室射血分数)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccd530104305, createdName=liuxiaona, createdTime=Sat Oct 06 09:13:00 CST 2018, time=2018-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854111, encodeId=b05c185411118, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Fri May 10 07:13:00 CST 2019, time=2019-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325917, encodeId=5e25132591e49, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Thu Aug 02 06:13:00 CST 2018, time=2018-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373421, encodeId=865713e3421c2, content=<a href='/topic/show?id=2fd051939ab' target=_blank style='color:#2F92EE;'>#心衰患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51939, encryptionId=2fd051939ab, topicName=心衰患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Thu Aug 02 06:13:00 CST 2018, time=2018-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=335458, encodeId=9b203354581e, content=好文章学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b5a62240667, createdName=张新亮1853311252142e2fm, createdTime=Wed Aug 01 07:05:24 CST 2018, time=2018-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=335406, encodeId=4d65335406a5, content=学习啦, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ac82155377, createdName=1201e5c5m39暂无昵称, createdTime=Tue Jul 31 23:38:12 CST 2018, time=2018-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=335360, encodeId=0fa933536088, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba101609906, createdName=happsf, createdTime=Tue Jul 31 16:14:10 CST 2018, time=2018-07-31, status=1, ipAttribution=)]
    2019-05-10 hbwxf
  3. [GetPortalCommentsPageByObjectIdResponse(id=1700464, encodeId=3ab61e004647d, content=<a href='/topic/show?id=49fa4801038' target=_blank style='color:#2F92EE;'>#左室射血分数#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48010, encryptionId=49fa4801038, topicName=左室射血分数)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccd530104305, createdName=liuxiaona, createdTime=Sat Oct 06 09:13:00 CST 2018, time=2018-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854111, encodeId=b05c185411118, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Fri May 10 07:13:00 CST 2019, time=2019-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325917, encodeId=5e25132591e49, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Thu Aug 02 06:13:00 CST 2018, time=2018-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373421, encodeId=865713e3421c2, content=<a href='/topic/show?id=2fd051939ab' target=_blank style='color:#2F92EE;'>#心衰患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51939, encryptionId=2fd051939ab, topicName=心衰患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Thu Aug 02 06:13:00 CST 2018, time=2018-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=335458, encodeId=9b203354581e, content=好文章学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b5a62240667, createdName=张新亮1853311252142e2fm, createdTime=Wed Aug 01 07:05:24 CST 2018, time=2018-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=335406, encodeId=4d65335406a5, content=学习啦, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ac82155377, createdName=1201e5c5m39暂无昵称, createdTime=Tue Jul 31 23:38:12 CST 2018, time=2018-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=335360, encodeId=0fa933536088, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba101609906, createdName=happsf, createdTime=Tue Jul 31 16:14:10 CST 2018, time=2018-07-31, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1700464, encodeId=3ab61e004647d, content=<a href='/topic/show?id=49fa4801038' target=_blank style='color:#2F92EE;'>#左室射血分数#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48010, encryptionId=49fa4801038, topicName=左室射血分数)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccd530104305, createdName=liuxiaona, createdTime=Sat Oct 06 09:13:00 CST 2018, time=2018-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854111, encodeId=b05c185411118, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Fri May 10 07:13:00 CST 2019, time=2019-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325917, encodeId=5e25132591e49, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Thu Aug 02 06:13:00 CST 2018, time=2018-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373421, encodeId=865713e3421c2, content=<a href='/topic/show?id=2fd051939ab' target=_blank style='color:#2F92EE;'>#心衰患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51939, encryptionId=2fd051939ab, topicName=心衰患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Thu Aug 02 06:13:00 CST 2018, time=2018-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=335458, encodeId=9b203354581e, content=好文章学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b5a62240667, createdName=张新亮1853311252142e2fm, createdTime=Wed Aug 01 07:05:24 CST 2018, time=2018-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=335406, encodeId=4d65335406a5, content=学习啦, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ac82155377, createdName=1201e5c5m39暂无昵称, createdTime=Tue Jul 31 23:38:12 CST 2018, time=2018-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=335360, encodeId=0fa933536088, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba101609906, createdName=happsf, createdTime=Tue Jul 31 16:14:10 CST 2018, time=2018-07-31, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1700464, encodeId=3ab61e004647d, content=<a href='/topic/show?id=49fa4801038' target=_blank style='color:#2F92EE;'>#左室射血分数#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48010, encryptionId=49fa4801038, topicName=左室射血分数)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccd530104305, createdName=liuxiaona, createdTime=Sat Oct 06 09:13:00 CST 2018, time=2018-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854111, encodeId=b05c185411118, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Fri May 10 07:13:00 CST 2019, time=2019-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325917, encodeId=5e25132591e49, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Thu Aug 02 06:13:00 CST 2018, time=2018-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373421, encodeId=865713e3421c2, content=<a href='/topic/show?id=2fd051939ab' target=_blank style='color:#2F92EE;'>#心衰患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51939, encryptionId=2fd051939ab, topicName=心衰患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Thu Aug 02 06:13:00 CST 2018, time=2018-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=335458, encodeId=9b203354581e, content=好文章学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b5a62240667, createdName=张新亮1853311252142e2fm, createdTime=Wed Aug 01 07:05:24 CST 2018, time=2018-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=335406, encodeId=4d65335406a5, content=学习啦, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ac82155377, createdName=1201e5c5m39暂无昵称, createdTime=Tue Jul 31 23:38:12 CST 2018, time=2018-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=335360, encodeId=0fa933536088, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba101609906, createdName=happsf, createdTime=Tue Jul 31 16:14:10 CST 2018, time=2018-07-31, status=1, ipAttribution=)]
    2018-08-01 张新亮1853311252142e2fm

    好文章学习了

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1700464, encodeId=3ab61e004647d, content=<a href='/topic/show?id=49fa4801038' target=_blank style='color:#2F92EE;'>#左室射血分数#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48010, encryptionId=49fa4801038, topicName=左室射血分数)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccd530104305, createdName=liuxiaona, createdTime=Sat Oct 06 09:13:00 CST 2018, time=2018-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854111, encodeId=b05c185411118, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Fri May 10 07:13:00 CST 2019, time=2019-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325917, encodeId=5e25132591e49, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Thu Aug 02 06:13:00 CST 2018, time=2018-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373421, encodeId=865713e3421c2, content=<a href='/topic/show?id=2fd051939ab' target=_blank style='color:#2F92EE;'>#心衰患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51939, encryptionId=2fd051939ab, topicName=心衰患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Thu Aug 02 06:13:00 CST 2018, time=2018-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=335458, encodeId=9b203354581e, content=好文章学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b5a62240667, createdName=张新亮1853311252142e2fm, createdTime=Wed Aug 01 07:05:24 CST 2018, time=2018-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=335406, encodeId=4d65335406a5, content=学习啦, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ac82155377, createdName=1201e5c5m39暂无昵称, createdTime=Tue Jul 31 23:38:12 CST 2018, time=2018-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=335360, encodeId=0fa933536088, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba101609906, createdName=happsf, createdTime=Tue Jul 31 16:14:10 CST 2018, time=2018-07-31, status=1, ipAttribution=)]
    2018-07-31 1201e5c5m39暂无昵称

    学习啦

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1700464, encodeId=3ab61e004647d, content=<a href='/topic/show?id=49fa4801038' target=_blank style='color:#2F92EE;'>#左室射血分数#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48010, encryptionId=49fa4801038, topicName=左室射血分数)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccd530104305, createdName=liuxiaona, createdTime=Sat Oct 06 09:13:00 CST 2018, time=2018-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854111, encodeId=b05c185411118, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Fri May 10 07:13:00 CST 2019, time=2019-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325917, encodeId=5e25132591e49, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Thu Aug 02 06:13:00 CST 2018, time=2018-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373421, encodeId=865713e3421c2, content=<a href='/topic/show?id=2fd051939ab' target=_blank style='color:#2F92EE;'>#心衰患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51939, encryptionId=2fd051939ab, topicName=心衰患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Thu Aug 02 06:13:00 CST 2018, time=2018-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=335458, encodeId=9b203354581e, content=好文章学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b5a62240667, createdName=张新亮1853311252142e2fm, createdTime=Wed Aug 01 07:05:24 CST 2018, time=2018-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=335406, encodeId=4d65335406a5, content=学习啦, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ac82155377, createdName=1201e5c5m39暂无昵称, createdTime=Tue Jul 31 23:38:12 CST 2018, time=2018-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=335360, encodeId=0fa933536088, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba101609906, createdName=happsf, createdTime=Tue Jul 31 16:14:10 CST 2018, time=2018-07-31, status=1, ipAttribution=)]
    2018-07-31 happsf

    学习

    0

相关资讯

JACC:蛋白酶抑制剂会增加HIV伴心衰患者死亡率

HIV患者的心衰发生风险会增加。蛋白酶抑制剂(PIs)与不良的心脏重塑和血管事件相关,但PIs在HIV伴心衰的患者中的使用情况尚不清楚。本研究的目的旨在比较HIV伴心衰患者接受包含PIs的治疗和不包含PIs(NPI)治疗的临床特征的差异。本研究纳入了394名接受抗逆转录病毒治疗的因心衰住院的HIV患者(平均年龄60 ± 9.5岁,女性占47%,CD4计数292 ± 206 个/mm3),其中145

JACC:低剂量利伐沙班在亚洲房颤人群的安全性和有效性研究

低剂量利伐沙班(10mg/天)在亚洲房颤患者中已被广泛使用,但其有效性尚缺乏全面的评估。在亚洲人群中,低剂量利伐沙班是否与标准剂量利伐沙班一样有效尚不清楚。本研究的 目的旨在评估亚洲房颤患者服用标准剂量利伐沙班(15或20mg/天)和低剂量利伐沙班(10mg/天)的安全性和有效性。本研究纳入了健康数据库中的6558名亚洲房颤患者,其中2373名和4185名患者分别接受了低剂量和标准剂量的利伐沙班治

Arter Throm Vas Bio:中老年阿姨注意了!化验单上这一指标可能并不能说明你的心血管

情人眼里出西施,人们总是带着主观性定义“好”和“坏”,胆固醇也不例外。通常,医生以定期监测“好胆固醇”(高密度脂蛋白)和“坏胆固醇”(低密度脂蛋白)的水平作为评估心血管健康的依据。但近日匹兹堡大学提供的新证据却驳斥了这一标准:特定类型的血液胆固醇测量可能不会降低老年妇女患心血管疾病的风险。

JACC:长链非编码RNA可调控心脏再生能力

成年哺乳动物的心脏由于缺乏有丝分裂能力而不能再生。本研究的目的旨在评估长链非编码RNA(lncRNAs)在成年心脏损伤后再生中的作用及机制。本研究发现一种lncRNA-CAREL在失去再生能力的新生小鼠(P7)心肌中表达量升高,通过Myh6介导的心肌特异性过表达lncRNA-CAREL转基因小鼠模型,发现该转基因小鼠心肌损伤后心肌细胞的分裂和增殖能力下降,通过病毒在体内敲降lncRNA-CAREL

盘点:JACC7月第5期研究一览

1. 低剂量利伐沙班在亚洲房颤人群的安全性和有效性研究DOI: 10.1016/j.jacc.2018.04.084http://www.onlinejacc.org/content/72/5/477低剂量利伐沙班(10mg/天)在亚洲房颤患者中已被广泛使用,但其有效性尚缺乏全面的评估。在亚洲人群中,低剂量利伐沙班是否与标准剂量利伐沙班一样有效尚不清楚。本研究的 目的旨在评估亚洲房颤患者服用标

JACC:Etripamil 鼻喷雾剂治疗阵发性室上速安全有效

目前,还没有能快速终止阵发性室上速的注射药物。本研究的目的旨在评估etripamil鼻喷雾剂(一种短效钙离子阻断剂)治疗阵发性室上速(SVT)的安全性和有效性。本研究的研究对象是因SVT行电生理检查的患者,SVT持续时间在5min以上的患者接受了安慰剂或不同剂量的etripamil鼻喷雾剂治疗。本研究的主要终点事件是药物治疗15min内的SVT转化率,次要终点事件包括转化所需的时间和不良反应事件。

Baidu
map
Baidu
map
Baidu
map